Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited 透 雲 生 物 科 技 集 團 有 限 公 司

(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

SUPPLEMENTAL ANNOUNCEMENT

DATE OF BOARD MEETING

Reference is made to the announcement of Touyun Biotech Group Limited (the "Company") dated 21 March 2022 (the "Announcement") in relation to the notice of board meeting of the Company. Unless otherwise defined herein, capitalized terms used in the announcement shall have the same meaning as those defined in the Announcement.

The Board would like to provide supplemental information in respect of the explanation on the delay of the publication of the annual results announcement which shall be agreed with the Company's auditors by 31 March 2022 in accordance with Rule 13.49 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:

The progress of the relevant audit field works in the People's Republic of China (the "PRC") has been disrupted in light of the quarantine measures and travel restrictions imposed in the PRC and Hong Kong due to the outbreak of the coronavirus disease (COVID-19).

Save as disclosed above, all other information in the Announcement shall remain unchanged.

By order of the Board

Touyun Biotech Group Limited

Wang Liang

Chairman

Hong Kong, 23 March 2022

As at the date of this announcement, the Board comprised the following directors:

Executive Directors

Mr. Wang Liang (Chairman)

Mr. Du Dong

Non-executive Directors

Mr. Chen Hui

Ms. Tian Yuze

Mr. Jia Wenjie

Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping

Mr. Ha Kee Choy Eugene

Mr. To Shing Chuen

Mr. Hu Guohua